抗凝与抗血小板治疗在不明来源栓塞性卒中各亚组中的比较:随机对照试验的荟萃分析
该研究对7项随机对照试验共14804例不明来源栓塞性卒中(ESUS)患者进行荟萃分析,比较抗凝与抗血小板治疗。抗凝组7406例,抗血小板组7398例。抗凝治疗与抗血小板治疗相比,复发性缺血性卒中风险相似(RR 0.91,95%CI 0.80-1.05;I²=0%)。在卵圆孔未闭(PFO)患者中,抗凝与显著降低的缺血性卒中风险相关(RR 0.59,95%CI 0.35-0.98;I²=0%)。
要点
- 在ESUS患者中,经验性抗凝治疗并不优于抗血小板治疗。
- PFO患者中抗凝治疗显示出降低缺血性卒中的潜力。
- 左心房扩大患者的获益因是否允许心脏监测而异。
核心结论
- 在ESUS患者中,经验性抗凝治疗并无益处,强调个体化治疗策略的重要性。
- 个体化策略应包括延长心脏监测以发现心房颤动,尤其是中重度左心房扩大的患者。
- 抗凝治疗在经医学治疗的PFO患者中显示出前景,其他亚组未从抗凝治疗中获益。
- 需要在ESUS亚组中进行大型前瞻性研究以验证本研究发现。
研究设计与样本
- 研究-level荟萃分析,纳入7项随机对照试验,共14804例ESUS患者,其中抗凝组7406例,抗血小板组7398例。
- 主要疗效结局为复发性缺血性卒中,安全性结局为大出血和死亡。
- 评估的亚组包括年龄、性别、卵圆孔未闭(PFO)存在、左心房扩大(LAE)和心房心脏病。
- 采用Cochrane偏倚风险工具2.0进行偏倚风险评估。
主要发现
- 抗凝治疗与抗血小板治疗相比,复发性缺血性卒中发生率相似(RR 0.91,95%CI 0.80-1.05;I²=0%)。
- 在合并PFO的ESUS患者中,抗凝治疗与显著降低的缺血性卒中风险相关(RR 0.59,95%CI 0.35-0.98;I²=0%)。
- 在左心房扩大患者中,允许随机化后心脏监测的试验中抗血小板治疗更优(RR 6.65,95%CI 1.26-35.08;I²=0%),而禁止心脏监测的试验中抗凝治疗更优(RR 0.25,95%CI 0.07-0.89)。
- 基于年龄、性别或心房心脏病存在的亚组未显示抗凝治疗优于抗血小板治疗。
关键数值与推荐
- 复发性缺血性卒中:抗凝 vs 抗血小板 RR 0.91(95%CI 0.80-1.05;I²=0%)。
- PFO亚组缺血性卒中:抗凝 vs 抗血小板 RR 0.59(95%CI 0.35-0.98;I²=0%)。
- 左心房扩大亚组(允许心脏监测试验):抗血小板 vs 抗凝 RR 6.65(95%CI 1.26-35.08;I²=0%)。
- 左心房扩大亚组(禁止心脏监测试验):抗凝 vs 抗血小板 RR 0.25(95%CI 0.07-0.89)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要在ESUS亚组中进行大型前瞻性研究以验证本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The term "embolic stroke of undetermined source" (ESUS) encompasses a substantial but heterogeneous population of patients with ischemic stroke, underscoring the importance of identifying personalized treatment strategies. In subgroups of patients randomized in ESUS trials, we evaluated the effectiveness of anticoagulation compared with antiplatelet therapy in secondary ischemic stroke prevention. METHODS: A study-level meta-analysis was conducted on randomized controlled trials of patients with ESUS, comparing anticoagulation with antiplatelet therapy. The primary efficacy outcome was recurrent ischemic stroke, and safety outcomes were major bleeding and death. Subgroups assessed were age, sex, presence of patent foramen ovale (PFO), left atrial enlargement (LAE), and atrial cardiopathy. Pooled risk ratios (RRs) were meta-analyzed. Cochrane Risk of Bias Tool 2.0 was used for risk-of-bias assessment. RESULTS: A total of 7 randomized controlled trials involving 14,804 patients were analyzed, with 7,406 patients treated with anticoagulation and 7,398 treated with antiplatelet therapy. Compared with antiplatelet therapy, anticoagulation was associated with a similar rate of recurrent ischemic stroke (RR 0.91, 95% CI 0.80-1.05; I2 = 0%). In ESUS with PFO, anticoagulation was associated with significantly lower risk of ischemic stroke (RR 0.59, 95% CI 0.35-0.98; I2 = 0%). Heterogeneity was present in those with LAE: antiplatelet therapy was superior in trials allowing cardiac monitoring after randomization (RR 6.65, 95% CI 1.26-35.08; I2 = 0%), but anticoagulation was superior in trials prohibiting cardiac monitoring after randomization (RR 0.25 95% CI 0.07-0.89). Subgroups based on age, sex, or presence of atrial cardiopathy did not benefit from anticoagulation over antiplatelet therapy. DISCUSSION: In this meta-analysis, an empiric anticoagulation approach is not beneficial for patients with ESUS. This finding highlights the importance of an individualized treatment strategy. Such a strategy should include prolonged cardiac monitoring for atrial fibrillation, particularly in patients with moderate-to-severe LAE. Anticoagulation treatment showed promise in patients with medically treated PFO. Other subgroups did not benefit from anticoagulation therapy. Large prospective studies within ESUS subgroups are needed to validate our findings.
引用
- Ghannam M, Al-Qudah AM, Alshaer QN, et al. Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source: A Meta-Analysis of Randomized Controlled Trials. Neurology. 2024. PMID: 39365971. doi:10.1212/WNL.0000000000209949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。